Correction to: Leukemia (2015) 29, 586–597; doi: 10.1038/leu.2014.245

It has come to our attention that a production error made by the Journal resulted in duplication of the immunoblot image from Figure 2a into the analogous position in Figure 2b, replacing the correct image for that panel. The complete, correct version of Figure 2 as originally submitted by the authors appears below. We thank the Journal for providing this correction.

Figure 2
figure 1

Inhibition of STAT3 reduces colony formation by TKI-resistant CML cells. (a, b) TKI-resistant CML cell lines were retrovirally transduced with shRNA targeting STAT3 (shSTAT3) or scrambled control (shSCR), and cultured in semisolid medium ± imatinib (1.0–2.5 μM). STAT3 and not STAT5 knockdown was confirmed by immunoblot analyses (a, b, right). shSTAT3 reduced colony formation of K562R (a, left, n=4) and AR230R (b, left, n=4) cells in the presence of imatinib, with no effect on parental TKI-sensitive controls. (c, d) TKI-resistant CML cell lines were transduced with dominant-negative STAT3 mutants (dnSTAT3) or empty vector (EV) and cultured in semisolid medium ± imatinib (1.0 μM). Inhibition of pSTAT3Y705 was confirmed by immunoblot analyses (c, d, right). dnSTAT3 reduced colony formation of K562R (c, left, n=4) and AR230R (d, left, n=3) cells with no effect on parental TKI-sensitive controls (n=2). (e, f) K562R (e, n=4) and AR230R (f, n=4) cells were incubated in methylcellulose semisolid medium with SF-1-066 (1–10 μM) ± imatinib (1.0 μM). SF-1-066 reduced colony formation of only TKI-resistant and not TKI-sensitive cells. (g) Mononuclear cells (MNCs) from peripheral blood of normal donors (n=2) or CMLCD34+ cells from newly diagnosed patients (n=4) were treated ex vivo with SF-1-066 (10 μM) ± imatinib (2.5 μM) in RM or HS-5 CM for 96 h followed by colony-forming assays. All data are represented as percent of controls. Error bars represent s.e.m. *P<0.05; **P<0.01; ***P<0.001.

Full size image